Concepedia

Author

Paul B. Chapman

Memorial Sloan Kettering Cancer CenterORCID

Also Known As

Chapman, Paul, P B Chapman, P Chapman, P. B. CHAPMAN, P. B. Chapman, P. CHAPMAN, P. Chapman, P.B. Chapman, PAUL B. CHAPMAN, Paul B Chapman

513

Publications

43.5K

Citations

74

H-Index

141

Concepts

All Affiliations

Memorial Sloan Kettering Cancer CenterCornell UniversityMassachusetts General HospitalUniversity of California, Los AngelesPeter MacCallum Cancer Centre
PB

About

Paul B. Chapman is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

47

91

18.5K

2

Health Sciences

13

15

4.7K

3

Engineering

3

3

191

4

Natural Sciences

2

2

37

5

Public Health

2

2

90

Paul B. Chapman

×

179

Publications

42.4K

Citations

73

H-Index

YearCitations

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman, Axel Hauschild, Caroline Robert,

New England Journal of Medicine

2011

7.6K

Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET

Héctor Peinado, Maša Alečković, Simon Lavotshkin,

Nature Medicine

2012

3.6K

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Keith T. Flaherty, Igor Puzanov, Kevin B. Kim,

New England Journal of Medicine

2010

3.5K

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Axel Hauschild, Jean‐Jacques Grob, Lev Demidov,

The Lancet

2012

2.9K

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Gideon Bollag, Peter Hirth, James Tsai,

Nature

2010

1.8K

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Ravid Straussman, Teppei Morikawa, Kevin Shee,

Nature

2012

1.7K

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Poulikos I. Poulikakos, Yogindra Persaud, Manickam Janakiraman,

Nature

2011

1.4K

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

Troy Z. Horvat, Nelly G. Adel, Thu-Oanh Dang,

Journal of Clinical Oncology

2015

1.1K

<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

Fei Su, Amaya Virós, Carla Milagre,

New England Journal of Medicine

2012

1K

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Grant A. McArthur, Paul B. Chapman, Caroline Robert,

The Lancet Oncology

2014

969

Page 1